PD1 stands for programmed death (of melanoma cells) and is an immunotherapy with a reported higher response rate than Yervoy. The prior therapies may become an issue when they number more than 3 I believe for the BMS PD1. I will double check on that. I don’t think we know if prior failure to Yervoy means failure on PD1 and certainly wouldn’t correlate to the small response rate of IL2 of 6%. Sometimes it is a good idea to go off Zelboraf and then back on. I hope this answers your questions.